Table 4.
Treatment outcomes of patients with and without KDIGO 3 acute kidney injury, and with two different formulations of intravenous colistin
| KDIGO 3 AKI | P-value | Intravenous colistin | ||||
|---|---|---|---|---|---|---|
| Yes, n = 41 | No, n = 154 | Locolin®, n = 95 | Colimycin®, n = 100 | |||
| Ventilator days (Median, IQR) | 36 (17–52) | 22 (13–42) | 0.036 | 28 (15–48) | 24 (13–47) | 0.048 |
| ICU stay (days) (Median, IQR) | 31 (19–47) | 30 (20–51) | 0.889 | 30 (19–47) | 31 (21–54) | 0.285 |
| Hospital stay (days) (Median, IQR) | 60 (38–94) | 53 (31–80) | 0.133 | 56 (35–87) | 50 (29–76) | 0.075 |
| Mortality | ||||||
| Day 28 | 14 (34.1%) | 62 (40.3%) | 0.476 | 34 (35.8%) | 42 (42%) | 0.374 |
| Discharge | 28 (68.3%) | 91 (59.1%) | 0.283 | 56 (58.9%) | 63 (63%) | 0.562 |
AKI acute kidney injury, ICU intensive care unit, IQR interquartile range